AMAG Pharmaceuticals, Inc.Appoints Gary J. Zieziula as Executive Vice President and Chief Commercial Officer

LEXINGTON, Mass., Apr 27, 2010 (BUSINESS WIRE) –AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company
focused on the development and commercialization of a therapeutic iron
compound to treat anemia and novel imaging agents to aid in the
diagnosis of cancer and cardiovascular disease today announced the
appointment of Gary J. Zieziula as Executive Vice President and Chief
Commercial Officer. In this newly created position, Mr. Zieziula will be
responsible for the company’s commercial organization including sales,
managed markets and reimbursement, marketing, market research,
commercial analytics, and sales operations. He will lead the company’s
global commercial strategy in support of the planned label expansion for
Feraheme(R) (ferumoxytol) Injection for intravenous (IV) use
across all therapeutic indications and imaging applications and evaluate
the commercial attractiveness of potential in-licensing opportunities.
Mr. Zieziula will report directly to Brian J.G. Pereira, M.D., President
and CEO.

Mr. Zieziula has over 25 years of pharmaceutical experience, most
recently serving as the Managing Director, Pharmaceuticals for Roche
(Hellas) S.A. in Greece. Since joining Roche in 2001, he has held
several key sales and marketing positions, including Head of Commercial
Operations, Specialty Care at Roche USA, where he was responsible for
oncology, transplant, anti-infectives and antivirals/HIV products, which
together had total annual revenues exceeding $2.5 billion during Mr.
Zieziula’s tenure.

“Gary’s global experience in commercializing a broad range of
therapeutic products will serve AMAG well as we look to expand the label
for Feraheme,” said Brian J. G. Pereira, M.D., President and
Chief Executive Officer of AMAG Pharmaceuticals, Inc. “The addition of
Gary further strengthens our management team as we seek to unlock the
value of Feraheme for patients with iron deficiency anemia with
or without chronic kidney disease around the world, as well as the
potential of ferumoxytol as an imaging agent.”

Prior to joining Roche, Mr. Zieziula held positions of Vice President
Sales, Cardiovascular Metabolic Products, as well as Vice President,
Managed Health Care Sales and Marketing at Bristol-Myers Squibb (BMS).
Prior to BMS, he had a 16-year career at Merck & Co. where he held
several senior commercial roles, including Vice President of Sales and
Operations of North America for Merck’s Vaccine division.

Mr. Zieziula holds a B.S. in Business Administration from the State
University of New York at Buffalo and an M.B.A. from Canisius College,
Buffalo, NY.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes
its proprietary technology for the development and commercialization of
a therapeutic iron compound to treat iron deficiency anemia and novel
imaging agents to aid in the diagnosis of cancer and cardiovascular
disease. On June 30, 2009, AMAG received approval from the U.S. Food and
Drug Administration to market Feraheme(R) (ferumoxytol) Injection for
intravenous (IV) use for the treatment of iron deficiency anemia in
adult chronic kidney disease patients. For additional company and
product information, please visit

Forward Looking Statement

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
other federal securities laws. Any statements contained herein which do
not describe historical facts, including but not limited to, statements
regarding our planned label expansion of Feraheme and Mr. Zieziula’s
role in support of that planned expansion, and the potential of
ferumoxytol as an imaging agent, are forward looking statements which
involve risks and uncertainties that could cause actual results to
differ materially from those discussed in such forward looking
statements. Such risks and uncertainties include: (1) uncertainties
regarding our ability to successfully compete in the intravenous iron
replacement market both in the U.S. and outside the U.S., (2)
uncertainties regarding our ability to successfully and timely complete
our clinical development programs and obtain regulatory approval for Feraheme
in territories outside of the U.S., (3) the fact that we have limited
experience developing and commercializing a pharmaceutical product on
our own or with a partner like Takeda, particularly outside of the U.S.,
(4) uncertainties regarding our ability to ensure favorable coverage,
pricing and reimbursement for Feraheme, (5) uncertainties
regarding our ability to manufacture Feraheme, (6) uncertainties
relating to our patents and proprietary rights, (7) the fact that
significant safety or drug interaction problems could arise with respect
to Feraheme, and (8) other risks identified in our Securities and
Exchange Commission filings, including our Annual Report on Form 10-K
for the year ended December 31, 2009. We caution you not to place undue
reliance on any forward-looking statements, which speak only as of the
date they are made. We disclaim any obligation to publicly update or
revise any such statements to reflect any change in expectations or in
events, conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will differ
from those set forth in the forward-looking statements.

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.

SOURCE: AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals
Amy Sullivan, 617-498-3303
Carol Miceli, 617-498-3361